Akari Therapeutics, Plc filed a registration statement on Form S-8 with the U.S. Securities and Exchange Commission on October 30, 2026, to register additional shares issuable under its 2023 Equity Incentive Plan.

Key Highlights

  • Shares registered: 144,000,000,000 additional ordinary shares, par value $0.000000005 per share, equivalent to 1,800,000 American Depositary Shares.
  • Governing plan: Shares are issuable under the Akari Therapeutics, Plc 2023 Equity Incentive Plan, as amended.
  • Incorporation by reference: The filing incorporates prior S-8 registration statements filed under File Nos. 333-274954 and 333-289057.
  • Company classification: Akari Therapeutics is classified as a non-accelerated filer and a smaller reporting company.
  • Agent for service: Abizer Gaslightwala, President and Chief Executive Officer, is named as the agent for service, located at 401 East Jackson Street, Suite 3300, Tampa, FL 33602.
  • Legal opinion: Greenberg Traurig, LLP (U.K.) provided the opinion on the legality of the securities being registered, filed as Exhibit 5.1.

Akari Therapeutics Expands 2023 Equity Incentive Plan Share Pool

Akari Therapeutics, Plc, a public company incorporated under the laws of England and Wales and operating in the biopharmaceutical sector, filed a registration statement on October 30, 2026, to register 144,000,000,000 ordinary shares with a par value of $0.000000005 per share. According to the filing, these shares are the equivalent of 1,800,000 American Depositary Shares and are issuable under the company's 2023 Equity Incentive Plan, as amended. The company's principal executive offices are listed at 401 East Jackson Street, Suite 3300, Tampa, FL 33602.

The filing relies on an incorporation-by-reference approach permitted under Instruction E of Form S-8, according to the registrant. The contents of prior registration statements filed under File Nos. 333-274954 and 333-289057 are incorporated by reference, with Part II provisions modified as set forth in the current filing. Among the documents incorporated by reference are the company's Annual Report for the year ended December 31, 2025, filed March 30, 2026; Quarterly Reports for the quarters ended March 31, 2026, and June 30, 2026; and multiple Current Reports on Form 8-K filed at various dates through October 30, 2026.

The filing also discloses that, pursuant to the company's Articles of Association and to the extent permitted by the U.K. Companies Act of 2006, directors and officers are entitled to indemnification against liabilities incurred in connection with their roles. The company additionally provides directors' and officers' liability insurance, according to the filing. BDO USA, P.C. is identified as the company's independent registered public accounting firm, with its consent filed as Exhibit 23.2.

What Was Disclosed

Akari Therapeutics, Plc registered 144,000,000,000 additional ordinary shares (equivalent to 1,800,000 American Depositary Shares) issuable under its 2023 Equity Incentive Plan, as amended, through a Form S-8 registration statement filed October 30, 2026.